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ABSTRACT Pyocin S5 (PyoS5) is a potent protein bacteriocin that eradicates the hu-
man pathogen Pseudomonas aeruginosa in animal infection models, but its import
mechanism is poorly understood. Here, using crystallography, biophysical and bio-
chemical analyses, and live-cell imaging, we define the entry process of PyoS5 and
reveal links to the transport mechanisms of other bacteriocins. In addition to its
C-terminal pore-forming domain, elongated PyoS5 comprises two novel tandemly re-
peated kinked 3-helix bundle domains that structure-based alignments identify as
key import domains in other pyocins. The central domain binds the lipid-bound com-
mon polysaccharide antigen, allowing the pyocin to accumulate on the cell surface. The
N-terminal domain binds the ferric pyochelin transporter FptA while its associated disor-
dered region binds the inner membrane protein TonB1, which together drive import of
the bacteriocin across the outer membrane. Finally, we identify the minimal require-
ments for sensitizing Escherichia coli toward PyoS5, as well as other pyocins, and suggest
that a generic pathway likely underpins the import of all TonB-dependent bacteriocins
across the outer membrane of Gram-negative bacteria.
IMPORTANCE Bacteriocins are toxic polypeptides made by bacteria to kill their com-
petitors, making them interesting as potential antibiotics. Here, we reveal unsus-
pected commonalities in bacteriocin uptake pathways, through molecular and cellu-
lar dissection of the import pathway for the pore-forming bacteriocin pyocin S5
(PyoS5), which targets Pseudomonas aeruginosa. In addition to its C-terminal pore-
forming domain, PyoS5 is composed of two tandemly repeated helical domains that
we also identify in other pyocins. Functional analyses demonstrate that they have
distinct roles in the import process. One recognizes conserved sugars projected from
the surface, while the other recognizes a specific outer membrane siderophore
transporter, FptA, in the case of PyoS5. Through engineering of Escherichia coli cells,
we show that pyocins can be readily repurposed to kill other species. This suggests
basic ground rules for the outer membrane translocation step that likely apply to
many bacteriocins targeting Gram-negative bacteria.
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Bacteria living within communities do so through cooperation and antagonism.Forms of antagonism whereby one bacterium targets another are important for
maintaining the stable coexistence of bacteria within microbiomes and are deployed by
pathogens and commensals alike to kill competitors (1). Antagonism occurs via several
routes, the most common being bacteriocins, contact-dependent inhibition, or type VI
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secretion. Of these, only the release of bacteriocins does not rely on physical contact
between bacterial cells. Bacteriocin production generally occurs following a stress
signal, such as DNA damage, inducing expression and release of the bacteriocin from
autolysed cells (2). The bacteriocin then diffuses through the medium to kill a neigh-
boring cell. Bacteriocins range in size from small peptides to large proteins, with both
types currently being evaluated/developed as antimicrobials against multidrug-
resistant bacteria (3, 4). In many instances, however, developments are hindered by a
lack of understanding as to how these molecules work. In the case of protein bacte-
riocins, extensive sequence diversification and homologous recombination further
hamper efforts to find generic mechanisms of uptake. Here, we focus on the uptake
mechanism of PyoS5, a protein bacteriocin that specifically targets the opportunistic
human pathogen Pseudomonas aeruginosa and that was shown recently in animal
models to be more effective at clearing lung infections than was tobramycin, the
antibiotic generally used to treat P. aeruginosa in cystic fibrosis patients (5). Through a
structure-led approach, we deconstruct the energized uptake pathway of PyoS5 and
show that its transport across the outer membrane likely represents the default
pathway for all TonB-dependent bacteriocins.
There is a pressing need for new antibiotics against Gram-negative bacteria, in
particular for P. aeruginosa, which has been designated a priority pathogen (6). The
intrinsic low permeability of its outer membrane renders P. aeruginosa insensitive to
many classes of antibiotics. Many strains also express multiple drug efflux pumps and
carbapenemases, making P. aeruginosa one of the major causes of nosocomial infec-
tions in the developed and developing world. One class of molecule that readily
translocates across the impervious outer membrane of P. aeruginosa to deliver a
cytotoxin is the S-type pyocins, which are 40- to 90-kDa protein bacteriocins made by
P. aeruginosa. Indeed, a recent survey showed that 85% of P. aeruginosa strains
encode nuclease-type pyocins within their genomes (7), hinting at the importance of
these protein antibiotics to interstrain competition.
S-type pyocins (here, pyocins) belong to a broad group of protein bacteriocins that
includes colicins which kill Escherichia coli, as well as bacteriocins that target other
Gram-negative bacteria, such as Klebsiella pneumoniae, Serratia marcescens, and Yersinia
pestis. Colicins, like pyocins, exploit the proton motive force (PMF) to translocate
through the cell envelope to deliver a cytotoxic domain, typically a pore-forming
domain or a nuclease that cleaves DNA, rRNA, or tRNA (8). Also like colicins, pyocins are
multidomain toxins, and their constituent domains are associated with binding outer
membrane receptors and the import process itself. There are currently several struc-
tures for intact colicins in the Protein Data Bank (PDB) but only two for pyocins, PaeM
and L1 (9, 10). However, PaeM and L1 are atypical among the bacteriocins due to their
small sizes (14 kDa for PaeM and 28 kDa for L1 compared to50 kDa for most pyocins).
Consequently, we know very little about the structural biology of typical pyocins found
in P. aeruginosa genomes. Structural data are important to understanding bacteriocin
uptake mechanisms, especially since the domain arrangement of pyocins is different
from that of colicins. The receptor-binding domains are centrally located in colicins, and
their membrane translocation domains are at the N terminus, whereas in pyocins, the
order is reported to be reversed (11). This change in relative domain orientation would
mean a fundamental difference in how these molecules are transported across the
outer membrane.
PyoS5 delivers a pore-forming domain across the outer membrane to depolarize the
cell, while PyoS5-producing cells are protected against the action of the toxin by ImS5,
a small membrane-localized immunity protein (12). Previous work has shown that
PyoS5 binds the lipopolysaccharide (LPS)-anchored common polysaccharide antigen
(CPA), which is identical across P. aeruginosa strains (13) and is a major surface antigen
in cystic fibrosis isolates (14), and that PyoS5 susceptibility depends on the ferric
pyochelin transporter FptA (15). Here, we delineate how PyoS5, by parasitizing FptA
and CPA in the outer membrane and in conjunction with proton motive force (PMF)-
linked TonB1 in the inner membrane, delivers its cytotoxic domain into P. aeruginosa.
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By defining the functionality of all constituent domains of PyoS5, we show that pyocins
and colicins are similarly constructed with respect to the relative positions of the
receptor-binding and translocation domains, a conclusion reinforced by the demon-
stration that PyoS5 can kill suitably engineered E. coli strains.
RESULTS AND DISCUSSION
The structure of PyoS5 reveals a novel domain architecture. PyoS5 was ex-
pressed and purified from E. coli cells (see Materials and Methods). The 57-kDa toxin
was monomeric in solution and active against P. aeruginosa strains at subnanomolar
concentrations (see Fig. S1 in the supplemental material). The protein crystallized in the
P21 space group, and the structure was solved by a combination of single-wavelength
anomalous diffraction and molecular replacement to a resolution of 2.2 Å (Fig. 1A and
Table S1) (see Materials and Methods). The first 39 residues were absent from the final
model and presumed to be unstructured; we refer to this below as the “disordered
region.” Otherwise, continuous electron density was observed for the entirety of the
remaining protein sequence (residues 40 to 498). The structure shows that PyoS5 is an
elongated, -helical protein measuring 36 Å on the short axis and 195 Å on the long
axis. Colicins are similarly long proteins and have disordered N termini (16–18). The
extended conformation was confirmed by small-angle X-ray scattering (SAXS) data; 93% of
the modeled PyoS5 residues were within the SAXS envelope (Fig. S2A and B). Also similar
to colicins is the prevalence of an -helical structure in PyoS5. PyoS5 contains 17 helices, the
high preponderance of helical structure likely reflecting the need to forcibly unfold the
toxin during transport into a cell and the lower forces known to be required for unfolding
helices relative to -sheets (reviewed in reference 19).
The structure of PyoS5 is composed of three ordered domains (Fig. 1A). The
C-terminal domain (domain 3, residues 315 to 498) has the canonical 10-helix bundle
fold of a pore-forming domain found in colicins (20), which is consistent with the killing
FIG 1 Crystal structure of PyoS5. (A) The 2.2-Å crystal structure of PyoS5 (residues 40 to 505). The first
kTHB domain is in red (residues 40-196), the second kTHB is in gray (residues 195-315), and the
pore-forming domain is in black (residues 316-505). Residues 2 to 39 are not resolved and are repre-
sented (to scale) by a red dashed line. (B) Structural alignment of PyoS540–196 (red) and PyoS5194–315
(gray), with an RMSD of 2.5 Å. Residues 123 to 162 (pink) are not conserved in PyoS5194–315 and were
excluded from the alignment. (C) Structural alignment of PyoS5 kTHB domains (red and gray) with that
from PyoS2 (teal), with an RMSD of 4.1 Å. PyoS5 residues 40 to 213 are shown, with residues 123 to 156
excluded, and PyoS2 residues 46 to 206 are shown, with residues 124 to 151 excluded. (D) Interactions
within domain 1 (red) and domain 2 (gray) are not conserved, as illustrated by the exemplary interactions
shown. Electron density is shown, with a cutoff of 1 .
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activity of PyoS5 (12). Previous studies have highlighted that the protective immunity
proteins of pore-forming domains within colicins fall into two subgroups, although the
functional significance of this is unclear. Immunity proteins against colicins A, B, and N
(the so-called A type) have four transmembrane helices, while those against colicins E1,
Ia, and K (the so-called E1 type) have three transmembrane helices (20). Based on the
predicted number of transmembrane helices of its immunity protein, the pore-forming
domain of PyoS5 belongs to the E1 type (21). Through detailed structural comparisons
of all pore-former domains with that of PyoS5, we identified a clear structural difference
between the pore-forming domains of the A and E1 groups (Fig. S2C). Specifically, this
difference relates to the positioning of helices 1 and 5 of the domain with respect to
each other; in A-type structures, helix 1 is positioned close to the center of the domain,
pushing out helix 5, while in E1-type structures, helix 5 is located closer to the center
of the domain. These pore-forming domain structures represent the ground state of the
ionophore before depolarization of the inner membrane. We speculate that the struc-
tural alterations evident in the A and E1 groups may reflect differences in the way each
class of pore-forming domain is recognized by its particular type of immunity protein
before insertion in the bacterial inner membrane.
The other structured domains of PyoS5 are also helical bundles but of a novel fold.
Domain 1 comprises residues 40 to 194, while domain 2 comprises residues 195 to 315.
The core structural motif of each domain is a kinked three-helix bundle (kTHB). The two
kTHB domains are structurally similar to each other (superposition root mean square
deviation [RMSD], 2.5 Å) but share little sequence identity (12%) (Fig. 1B). Each kTHB
domain is composed of a kinked helix I connected to a straight helix II by a loop. Helix
II packs against both helix I and a third straight helix, helix III. The connection between
helices II and III varies between the two copies of the fold. In domain 1, this connection
is composed of three short helical turns, while in domain 2, it is a loop. The other
striking feature of the kTHB structural motif is that the third helix from each domain
extends into the next domain of the pyocin; helix III of domain 1 extends over 90 Å into
domain 2, where it forms helix I, while helix III of domain 2 extends over 90 Å to the
pore-forming domain of the toxin. The kTHB fold is stabilized predominantly by
hydrophobic interactions mediated by aliphatic amino acid side chains and, in one
instance, aromatic stacking (Tyr207 to Tyr280, domain 2) (Fig. 1D). None of these
stabilizing interactions are conserved.
Recently, White et al. reported the structure of the N-terminal domain of the
nuclease pyocin PyoS2 bound to the outer membrane protein FpvAI (22). We found by
structural superposition that the kTHB domain 1 of PyoS5 is structurally similar to this
domain of PyoS2 (Fig. 1C), and the sequence similarity of 75% between the second
domains of PyoS5 and PyoS2 suggests similar structures here as well (Fig. S2D and E).
Sequence similarities of domains in pyocins S1, SD1, SD2, S3, SD3, and S4 to the kTHB
domain also suggest these are common among pyocins (Fig. S2D). The structural
superposition of the PyoS5 and PyoS2 kTHB domains, without the small helices
connecting helix II and helix III in PyoS5, has an RMSD of 4.1 Å over 128 residues
(Fig. 1C).
We conclude that PyoS5 is an elongated bacteriocin comprising a disordered region
at its N terminus, two kTHB domains, which is a common structural platform for protein
bacteriocins targeting P. aeruginosa, and a C-terminal pore-forming domain. We next
set out to ascribe functions to each of the domains/regions of PyoS5 that transport the
pore-forming domain into P. aeruginosa cells.
Functional annotation of PyoS5 domains. We expressed and purified truncations
of PyoS5 that removed one or more domains/regions. These included PyoS51–315, in
which the pore-forming domain was removed, PyoS51–196, in which both domain 2 and
the pore-forming domain were deleted, and PyoS5194–315, which only contained do-
main 2. The constructs were folded, as determined by circular dichroism spectroscopy,
and their thermal melting temperatures largely recapitulated those found in intact
PyoS5 (Fig. S3).
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We first analyzed the capacity of PyoS5 and the various deletion constructs to bind
CPA in isothermal titration calorimetry (ITC) experiments. Heats of binding were ob-
served for PyoS51–315 and PyoS5194–315 but not PyoS51–196 (in 0.2 M Na-phosphate
buffer [pH 7.5]) (Fig. 2A to C and Table S2A). From these experiments, equilibrium
dissociation constant (Kd) values of 0.6 M for PyoS51–315 and 0.3 M for PyoS5194–315
were obtained, similar to that reported previously for intact PyoS5 binding CPA (13).
When polysaccharides derived from P. aeruginosa PAO1 Δrmd were used (that do not
contain CPA), no binding to PyoS5194–315 was detected (Fig. 2C). These results dem-
onstrate that the CPA-binding activity of PyoS5 resides within domain 2 and that the
CPA-binding function is not a conserved feature of the kTHB fold. Pyocins S2 and SD3
FIG 2 kTHB domain 2 binds CPA, kTHB domain 1 binds FptA, and the N-terminal disordered region binds TonB1.
(A and B) ITC data for PyoS51–315 titrated into P. aeruginosa PAO1 LPS-derived polysaccharide containing CPA and
OSA (closed circles) gives a Kd of 612 332 nM (A), and PyoS51–196 titrated into P. aeruginosa PAO1 LPS-derived
polysaccharide shows no binding (B). (C) ITC data for PyoS5194–315 titrated into P. aeruginosa PAO1 LPS-derived
polysaccharide gives a Kd of 269 44 nM. PyoS5194–315 titrated into P. aeruginosa Δrmd LPS-derived polysaccharide
containing OSA only (open circles) shows no binding. (A to C) Kd values and concentrations can be found in
Table S2B. All ITC experiments were performed in duplicate in 0.2 M Na-phosphate buffer (pH 7.5) at 25°C, and one
repeat is shown. Data were corrected for heats of dilution by subtracting the average of the last five injections and
fit to a model of single-site binding. (D) SPR data for FptA (0.03 to 32 M) binding to PyoS51–315 (closed circles; Kd,
6.5 0.4 M), PyoS51–196 (open circles; Kd, 7.1 0.7 M), or PyoS5194–315 (diamonds; no binding). PyoS51–315
achieves higher RU levels than does PyoS51–196 even though the binding affinity remains essentially unchanged.
Since the pyocin was immobilized randomly on the chip, this is likely due to the greater availability of FptA binding
sites in the larger (PyoS51–315) construct. (E) SPR data for FptA (0.03 to 32 M) binding to PyoS51–315 (closed circles;
Kd, 6.5 0.4 M) or PyoS51–315 Δ2–39 (open circles; Kd, 14.7 0.4 M). (F) SPR data for TonB1 (0.009 to 35 M)
binding to PyoS51–315 (closed circles; Kd, 241 9 nM) or PyoS51–315 Δ10–13 (open circles; no binding). (D to F) One
of three repeats is shown. All experiments were performed in parallel on the same chip in HBS-OG buffer at 25°C.
All ligands were immobilized by amine coupling, and sensorgram data were extracted and fit with a 1:1 binding
model. Kd values are presented in Table S2C.
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have also been shown previously to bind P. aeruginosa CPA sugars (13). Sequence
alignments show that each has a domain equivalent to that of domain 2 of PyoS5.
Indeed, the level of sequence identity across this region (39%) is far greater than that
between the two kTHB domains of PyoS5. Moreover, over half of the 45 identical
residues shared between pyocins S2, SD3, and S5 form a grooved surface that runs
perpendicular to the long axis of PyoS5 (Fig. S2E and S4). We infer that this conserved
groove is the CPA-binding site in these different pyocins, each of which nevertheless
delivers a different cytotoxic domain into P. aeruginosa.
PyoS5-mediated killing of P. aeruginosa cells requires the ferric pyochelin transporter
FptA, and the central region of the toxin (residues 151 to 300) has been implicated in
defining this specificity (15). This region corresponds largely to domain 2 in the PyoS5
crystal structure, which, as the work described above indicates, is involved in CPA
binding. We therefore investigated PyoS5 binding to FptA and identified the region
involved. Initially, we used native mass spectrometry (MS) to verify that PyoS5 binds
FptA (Table S2B). We then determined the affinity for the complex using surface
plasmon resonance (SPR) where the pyocin and various deletion constructs were
immobilized on the chip (Fig. 2D and Table S2C). These experiments determined the Kd
for the PyoS5-FptA complex to be 6.5 M (in 25 mM HEPES buffer [pH 7.5], 150 mM
NaCl, 1% [wt/vol] n-octyl--D-glucoside [-OG]). Upon the addition of ferric pyochelin
to our SPR experiments, the binding of PyoS5 to FptA reduced significantly (Fig. S5B),
suggesting that the binding sites for the pyocin and pyochelin overlap. This result was
confirmed by native-state MS experiments where PyoS5 dissociated preformed com-
plexes of ferric pyochelin bound to FptA (Fig. S5A). We next delineated the FptA
binding site in PyoS5. The deletion of domain 2 had a marginal effect on FptA binding,
while domain 2 alone showed no FptA binding (Fig. 2D and Table S2C). Deletion of the
disordered region at the N terminus of PyoS5 (residues 2 to 39) had a large effect on
the amount of FptA that could bind to the chip (Fig. 2E), suggesting that this was
affecting binding. However, closer examination indicated that binding was affected
only 2-fold (Table S2C) and that the impact of the truncation was likely due to restricted
access of FptA to its binding site on domain 1 in this construct (Fig. 2E and Table S2C).
In contrast, when the first 12 residues of the mature construct were deleted (Δ2–9 and
Δ10–13), binding to FptA remained unaffected (Table S2C). We conclude that the FptA
binding site in PyoS5 is predominantly localized to kTHB domain 1 with a minor
contribution from its associated disordered region at the N terminus.
All protein bacteriocins access the PMF via either the Tol or Ton system of Gram-
negative bacteria (generally referred to as group A and B toxins in the colicin literature,
respectively), which they use to drive translocation across the outer membrane (2). It
has yet to be established which of these systems is contacted by PyoS5. Typically,
Tol/Ton dependence is evaluated using deletion strains. We focused initially on Ton
dependence since deletion strains in P. aeruginosa PAO6609 are available (Tol is essential
in P. aeruginosa). P. aeruginosa harbors three tonB genes, tonB1, tonB2, and tonB3
(23–25). PAO6609 is a derivative of P. aeruginosa PAO1 and so is naturally immune to
PyoS5 because it harbors the ImS5 immunity gene (26). We therefore generated a
PyoS5-ColIa chimera in which the pore-forming domain of PyoS5 was substituted for
that of colicin Ia to overcome this immunity. PyoS5-ColIa was active against P. aerugi-
nosa PAO6609 and strains with tonB2 and tonB3 deleted (Fig. S6A). It was not possible
to test the susceptibility of a tonB1 deletion strain because the high levels of iron
needed for the growth of this strain diminished PyoS5-ColIa chimera susceptibility in
the parent P. aeruginosa PAO6609, most likely due to iron-dependent downregulation
of FptA expression (27). We therefore resorted to direct SPR binding assays to deter-
mine if PyoS5 bound purified TonB1 in vitro (see Materials and Methods for further
details). We found that TonB1 binds PyoS51–315 with an affinity of 230 nM in SPR
experiments (Fig. 2F and Table S2C). Moreover, a putative 9-residue TonB box, found in
TonB1-dependent transporters and bacteriocins utilizing TonB1, is also found in the
N-terminal disordered region of PyoS5 (residues 6 to 14). The deletion of residues 10 to
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13 abolished binding to TonB1, confirming this region to be the TonB1 binding site
(Fig. 2F and Table S2C).
In summary, through a combination of biophysical and structural approaches, we
have delineated the major binding interactions of PyoS5 with the P. aeruginosa cell
envelope. Of the two kTHB domains, domain 2 binds CPA, while domain 1 binds the
ferric pyochelin transporter FptA, with a minor contribution by the disordered region,
which in addition binds the inner membrane protein TonB1.
Surface accumulation and energized import of fluorescently labeled PyoS5
into P. aeruginosa PAO1 cells. We developed a fluorescence-based import assay for
PyoS5 where the transport of all its domains, barring the pore-forming domain, could
be visualized and where the energetics of import could be established. We replaced the
pore-forming domain of PyoS5 with a C-terminal cysteine residue and labeled this
residue with Alexa Fluor 488 (PyoS51–315-AF488). P. aeruginosa PAO1 cells were used in
these experiments since cytotoxic activity was not being monitored. PyoS51–315-AF488
readily labeled P. aeruginosa PAO1 cells (Fig. 3A). Trypsin treatment of these labeled
cells, to remove surface-bound PyoS5, reduced fluorescence intensity significantly
(8-fold), but fluorescence was still associated with cells (Fig. 3A and B). Inclusion of the
protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) with the trypsin
treatment completely eradicated this remaining fluorescence, suggesting that this
protected fluorescence was internalized due to the PMF (Fig. 3A and B). We next
generated AF488-labeled constructs where either domain 2 was removed (PyoS51–196-
AF488) or where only labeled domain 2 was added to cells (PyoS5194–315-AF488).
Removal of the CPA-binding domain (domain 1, PyoS51–196-AF488) decreased surface-
bound fluorescence in the absence of trypsin, while the addition of trypsin still revealed
internalized fluorescence (Fig. 3C). PyoS5194–315-AF488 (domain 2 construct), on the
other hand, labeled cells much less efficiently (likely due to its weak binding of CPA on
the surface), and all of this fluorescence was trypsin sensitive, suggesting no internal-
ization (Fig. 3C).
Repeating these assays with P. aeruginosa PAO1 ΔfptA cells or using PyoS51–315
Δ10–13-AF488, in which part of the TonB1 binding site (residues 10 to 13) was deleted,
showed that trypsin-protected fluorophores (i.e., imported molecules) were no longer
detected, consistent with PMF/TonB1-dependent import of PyoS5 across the outer
membrane via FptA (Fig. 3D andS7). Finally, import assays were conducted using P.
aeruginosa PAO1 Δrmd cells, which lack CPA. Surface-associated fluorescence of
PyoS51–315-AF488 and susceptibility to PyoS5-ColIa were much reduced in these cells,
consistent with CPA being required for surface accumulation of PyoS5, but imported
fluorescence in a domain 2 deletion was unaffected (Fig. 3E and S6B).
In summary, our fluorescence assays suggest that the import of PyoS5 occurs in two
stages. Initial binding to CPA via the central kTHB domain leads to accumulation on the
surface of P. aeruginosa. Thereafter, the first kTHB domain of the pyocin binds FptA in
the outer membrane, which also likely acts as the translocation channel, allowing
contact between the disordered TonB1 binding site of PyoS5 with TonB1 in the inner
membrane and PMF-driven import of the toxin (model presented below).
Engineering pyocin susceptibility in E. coli. As with most bacteriocins, pyocins are
specific for a subset of strains, in this case from P. aeruginosa, which reflects the array
of cell envelope interactions required for import. Yet, common principles are beginning
to emerge suggesting that generic import mechanisms may apply for all Gram-negative
bacteria that exploit protein bacteriocins. We therefore devised a test of this hypothesis
by engineering E. coli susceptibility toward PyoS5 utilizing our current understanding
of its import pathway.
Our strategy was based on first determining if the pore-forming domain of PyoS5,
if imported, could kill E. coli cells and then engineering the minimal requirements into
E. coli in order for PyoS5 to be recognized and transported. A similar strategy was
reported by Bosák et al., where E. coli was engineered to be susceptible to a bacteriocin
specific for Yersinia kristensenii (28). In the present work, we first showed that a chimera
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of the PyoS5 pore-forming domain fused to the C terminus of the colicin B translocation
and receptor-binding region (replacing colicin B’s own pore-forming domain) was
cytotoxic against E. coli BL21(DE3) cells. We next challenged E. coli BL21(DE3) cells
expressing P. aeruginosa FptA but saw no PyoS5 killing (Fig. 4). Rationalizing that E. coli
TonB may not recognize the TonB1 binding sites (Ton boxes) of FptA and/or PyoS5, we
also expressed a chimera of E. coli TonB (TonB1–102) fused to P. aeruginosa TonB1201–342
FIG 3 CPA accumulates PyoS5 at the cell surface while FptA and TonB1 mediate import. (A) Fluorescent labeling of live P.
aeruginosa PAO1 cells with PyoS51–315-AF488. Additionally, the effects of depleting the PMF with CCCP before incubation with
PyoS51–315-AF488 and of trypsin treatment to remove surface-exposed PyoS51–315-AF488 after incubation with PyoS51–315-AF488 were
examined. Scale bars 5m. (B) Quantification of the average cell fluorescence observed under different conditions tested in panel
A. (C) Fluorescent labeling of live P. aeruginosa PAO1 using PyoS51–315-AF488, PyoS51–196-AF488, and PyoS5194–315-AF488 with and
without trypsin treatment quantified to determine the average cell fluorescence. (D) Fluorescent labeling of live P. aeruginosa
PW8161 (ΔfptAmutant) and P. aeruginosa PAO1 using PyoS51–315-AF488, PyoS51–196-AF488, and PyoS5194–315-AF488 with and without
trypsin treatment was quantified to determine the average cell fluorescence. (E) Fluorescent labeling of live P. aeruginosa PAO1 Δrmd
and PAO1 using PyoS51–315-AF488, PyoS51–196-AF488, and PyoS5194–315-AF488 with or without trypsin treatment was quantified to
determine the average cell fluorescence. (A to E) **** indicates a P value below 0.0001 in Student’s t test; ns indicates nonsignificance.
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in E. coli BL21(DE3) cells expressing FptA. In this chimera, TonB-B1, the C-terminal
domain, and periplasmic regions of TonB are those from P. aeruginosa, but the
transmembrane domain that associates with TonB’s partner proteins ExbB and ExbD are
those from E. coli. Under these conditions, E. coli became sensitized to PyoS5-mediated
killing (Fig. 4). To determine the generality of this cross-species killing, we expressed the
fpvAI gene, which is recognized by PyoS2 and PyoS4, in E. coli cells expressing the E.
coli-P. aeruginosa TonB-B1 hybrid. This strain was sensitive to both PyoS2 and PyoS4 but
not to PyoS5 (Fig. S8).
We conclude that our engineered system is a simple means by which the import
apparatus required for bacteriocins can be readily defined. Indeed, through this work,
we discovered that PyoS4 is a TonB1-dependent bacteriocin. Importantly, our complete
functional characterization of PyoS5 demonstrates that the prevailing view of receptor-
binding and translocation domains being inverted in pyocins relative to colicins is not
correct. Instead, pyocins and colicins are organized in the same way, which likely
explains how a pyocin can be made to work in E. coli. They have central receptor-
binding domains (kTHB domain 2 in PyoS5) and N-terminally located translocation
domains (kTHB domain 1 and its associated disordered region). The confusion that has
emerged in the field, that N-terminal domains of pyocins represent their receptor-
binding domains, has arisen because pyocin interactions with their translocation
channels (e.g., PyoS2 with FpvAI [22]) can be much higher affinity than the interaction
of the pyocin with its initial CPA receptor. In summary, our results suggest that the
underlying mechanisms by which Ton-dependent bacteriocins cross the outer mem-
branes of the Enterobacteriales and Pseudomonadales, long thought to be unrelated, are
fundamentally the same.
Model for pyocin transport across the outer membrane of P. aeruginosa. White
et al. demonstrated recently that the N-terminal domain of PyoS2 translocates directly
through FpvAI (22). The mechanism of import is analogous to that of FpvAI’s cognate
siderophore ligand, ferripyoverdine; a labile portion of the transporter plug domain is
removed by TonB1, allowing the TonB1 binding site (TonB box) of PyoS2 to enter the
periplasm and activate import of the pyocin. Binding of PyoS2 to FpvAI is primarily
through a short polyproline region that lacks a regular secondary structure and mimics
pyoverdine. The principal binding site of PyoS5 for FptA is domain 1 and its associated
disordered region, which does not, however, have an equivalent polyproline sequence.
Its binding to FptA is also significantly weaker than that of PyoS2 for FpvAI. For both
PyoS2 and PyoS5, however, the initial association with P. aeruginosa is by their central
kTHB domains (domain 2 in PyoS5), which binds CPA embedded in the outer mem-
brane and allows the toxin to decorate the cell surface (13).
In Fig. 5, we present a unifying model for TonB1-dependent pyocin import based on
our data for PyoS5 and that presented by White et al. for PyoS2 (22). CPA binding likely
FIG 4 FptA and TonB1 constitute the minimal system for PyoS5 susceptibility in E. coli. (A to D)
Susceptibility to PyoS5 (3 and 60 M) was assessed for P. aeruginosa YHP17 (A), E. coli BL21(DE3)
expressing FptA (B), E. coli BL21(DE3) expressing TonB-B1 (C), and E. coli BL21(DE3) expressing FptA and
TonB-B1 (D). Zones of clearance are observed in all E. coli samples for the ColB PyoS5 (13 M) control (B
to D) and for both concentrations of PyoS5 in E. coli expressing FptA and TonB-B1 (D). In the P. aeruginosa
control, clearance zones were observed for PyoS5 (A).
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orients the pyocin horizontally with respect to the membrane since the predicted
CPA-binding groove in PyoS5 is perpendicular to the long axis of PyoS5. This orienta-
tion assumes that CPA molecules are projected vertically from the surface from their
LPS anchors. After this initial surface association, we postulate that pyocins use their
disordered N terminus to find their transporter, the binding of which causes the pyocin
to reorient, allowing the N-terminal kTHB domain to engage the transporter (as found
in the PyoS2-FpvAI complex). Similar “fishing pole” models have been proposed for
receptor-bound colicins finding translocator proteins, but in these instances, the re-
ceptor is generally an outer membrane protein (29). Following opening of the trans-
porter channel by TonB1, the pyocin’s own TonB1 binding site enters the periplasm. A
second PMF-dependent step then occurs in which TonB1 in conjunction with the PMF
unfolds the kTHB domain of the pyocin and pulls it through the transporter. Whether
this energized interaction is responsible for the entire pyocin entering the periplasm (as
shown in Fig. 5) or whether domain refolding in the periplasm contributes to the entry
process remains to be established.
MATERIALS AND METHODS
Pyochelin was synthesized as described previously (30). Chromatography columns were purchased
from GE Healthcare.
Strains and plasmids. All bacteria (Table 1) were cultured in LB (10 g/liter tryptone, 10 g/liter NaCl,
5 g/liter yeast extract [pH 7.2]) at 37°C at 120 rpm shaking, unless otherwise stated. Liquid cultures were
inoculated from single colonies on LB agar (1.5% [wt/vol]) plates. M9 medium (8.6 mM NaCl, 18.7 mM
NH4Cl, 42.3 mM Na2HPO4, 22.0 mM KH2PO4) was supplemented with 0.4% (wt/vol) glucose, 2 mM MgSO4,
and 0.1 mM CaCl2.
Molecular biology. Genes were amplified from genomic DNA or synthesized by Genewiz. Plasmids
were created by restriction enzyme digestion and ligation or whole plasmid mutagenesis. Chemically
competent E. coli NEB5 and BL21(DE3) strains were purchased from NEB. Antibiotics were used at the
following final concentrations: 100 g/ml ampicillin and 50 g/ml kanamycin, and 50 g/ml gentamicin,
all from stock solutions in water; and 37 g/ml chloramphenicol and 10 g/ml tetracycline from stock
solutions in ethanol.
Expression and purification of bacteriocins. PyoS5 and its derivatives, as well as ColB PyoS5,
PyoS5-ColIa, PyoS2, PyoS4, and ColIa were expressed heterologously (Table 2) from E. coli BL21(DE3) for
3 h at 37°C or overnight at 20°C while shaking at 120 rpm. For constructs containing the PyoS5
pore-forming domain (amino acid residues 315 to 498), the cells were cotransformed with pHB22, which
carries the ImS5 immunity protein, for increased yield. The bacteria were harvested at 5,050  g for
15 min at 10°C, resuspended in binding buffer (0.5 M NaCl, 20 mM Tris-HCl [pH 7.5]), and sonicated on
ice. They were then centrifuged at 12,500  g for 20 min at 4°C, filtered through a 0.45-m syringe filter,
loaded onto a 5-ml HisTrap high-performance (HP) column equilibrated in binding buffer, and eluted by
gradient elution using elution buffer (binding buffer plus 0.75 M imidazole). The protein was then
FIG 5 Model of PyoS5 import. (A) PyoS5 accumulates on the cell surface by binding to CPA through kTHB domain
2. (B) PyoS5 then contacts its outer membrane (OM) translocator, FptA, initially with its disordered N terminus, and
then through binding of kTHB domain 1. (C) Interactions between FptA and TonB1 possibly act to induce
movement of the receptor plug domain, allowing for the unstructured N terminus of PyoS5 to thread through the
receptor and access the periplasm. Following entry to the periplasm, the N terminus of PyoS5 binds to TonB1
though the TonB-box motif. The formation of the PyoS5-TonB1 complex enables coupling to inner membrane (IM)
protein targets of TonB1. (D) This coupling provides energy transduction from the PMF that facilitates the
translocation of PyoS5 through the outer membrane. (E) Finally, this results in PyoS5 translocation into the
periplasm.
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dialyzed into size exclusion buffer (150 mM NaCl, 20 mM Tris-HCl [pH 7.5]) using a 12- to 14-kDa
molecular weight cutoff membrane (Spectra/Por; Spectrum), filtered through a 0.45-m syringe filter,
and applied to a 26/60 Superdex 200 size exclusion chromatography column.
PyoS4 was expressed at 28°C in the presence of an additional copy of ImS4(pNGH243) and purified
on an S200 16/60 size exclusion column.
Mass spectrometry indicated that all bacteriocins purified without their N-terminal methionines, with
the exception of PyoS51–315 Δ2–20, PyoS5194–315, and PyoS5194–315-Cys.
TABLE 1 Bacterial strains used in this study
Strain Relevant characteristics Source (reference)
E. coli
NEB5 fhuA2 Δ(argF-lacZ)U169 phoA glnV44 80Δ(lacZ)M15
gyrA96 recA1 relA1 endA1 thi-1 hsdR17
New England BioLabs
BL21(DE3) fhuA2 [lon] ompT gal ( DE3) [dcm] ΔhsdS  DE3  
sBamHIo ΔEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21
Δnin5
New England BioLabs
TNE012 ompA ompB tsx (50)
P. aeruginosa
PAO1 Clinical isolate Manoil lab Washington
mutant library
YHP17 Clinical isolate This study
PAO6609 met-9011 amiE200 strA pvd-9 (26)
K1407 PAO6609 tonB1 (23, 51)
K1408 PAO6609 tonB2 (23)
MS231 PAO6609 tonB3 (52)
MS233 PAO6609 tonB2 tonB3 (52)
PW8161 PAO1 fptA Manoil lab Washington
mutant library
PAO1 Δrmd CPA deficient (53)
TABLE 2 Expression plasmids used in this study
Plasmid
name Protein expressed Description Parent vector
Source or
reference
pPW18 PyoS5 PyoS5 with a C-terminal His6 tag cloned into the NdeI/XhoI sites pET21a() This study
pHB18 PyoS51–315 PyoS51–315 with a C-terminal His6 tag cloned into the NdeI/XhoI sites pET21a() This study
pHB32 PyoS51–315-Cys Derivative of pHB18, containing PyoS51–315 with a C-terminal
cysteine followed by a C-terminal His6 tag
pET21a() This study
pHB40 PyoS51–315 Δ2–39 Derivative of pHB18 pET21a() This study
pHB42 PyoS51–315 Δ2–9 Derivative of pHB18 pET21a() This study
pHB41 PyoS51–315 Δ10–13 Derivative of pHB18 pET21a() This study
pHB43 PyoS51–315 Δ16–20 Derivative of pHB18 pET21a() This study
pHB46 PyoS51–315 Δ10–13-Cys Derivative of pHB32 pET21a() This study
pHB19 PyoS51–196 PyoS51–196 with a C-terminal His6 tag cloned into the NdeI/XhoI sites pET21a() This study
pHB33 PyoS51–196-Cys Derivative of pHB19, containing PyoS51–196 with a C-terminal
cysteine followed by a C-terminal His6 tag
pET21a() This study
pHB24 PyoS5194–315 PyoS5194–315 with a C-terminal His6 tag cloned into the NdeI/XhoI
sites
pET21a() This study
pHB34 PyoS5194–315-Cys Derivative of pHB24, containing PyoS5194–315 with a C-terminal
cysteine followed by a C-terminal His6 tag
pET21a() This study
pHB09 ColB PyoS5 ColB1–340 translationally fused to PyoS5303–498 with a C-terminal His6
tag cloned into the NdeI/XhoI sites
pET21a() This study
pHB47 PyoS5-ColIa PyoS51–315 translationally fused to ColIa485–626 with a C-terminal His6
tag cloned into the NdeI/XhoI sites
pET21a() This study
pHB22 ImS5 ImS5 with a stop codon cloned into the NdeI/XhoI sites pACYCDuet-1 This study
pHB04 FptA FptA with OmpF signal sequence cloned into the NcoI/SacI sites pBAD/His-MycB This study
pPW17 TonB1 TonB1109–342 with N-terminal His6 tag followed by TEV cleavage site,
cloned into the NcoI/SacI sites
pETM11 (22)
pHB25 TonB-B1 hybrid E. coli TonB1–102 translationally fused to P. aeruginosa TonB1201–342
cloned into the NdeI/XhoI sites
pACYCDuet-1 This study
pNGH131 ColIa ColIa with a C-terminal His6 tag cloned into the NdeI/XhoI sites pET21a This study
pNGH243 ImS4 ImS4-His6 cloned into the NcoI/HindIII sites pET24a This study
pNGH246 PyoS4-ImS4 PyoS4-ImS4-His6 cloned into the NdeI/XhoI sites pACYCDuet-1 This study
pPW02 PyoS2-ImS2 PyoS2-ImS2-His6 cloned into the NdeI/XhoI sites pET21a (22)
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Expression and purification of TonB1 soluble fragments. The TonB1 construct was purified by
HisTrap HP column, as described for PyoS5, and then incubated in 300 mM NaCl and 50 mM Tris-HCl (pH
7.0) with 0.07 mg/ml His6-tobacco etch virus protease (His6-TEV) at room temperature (RT) for 4.5 h.
TonB1 was then purified by affinity chromatography on a HisTrap HP column and by size exclusion
chromatography on a 26/60 Superdex 200 column.
Expression and purification of FptA. FptA purification was modeled after a previous BtuB purifi-
cation protocol (31). FptA was expressed heterologously from E. coli TNE012 at 37°C while shaking at
120 rpm in LB, and upon reaching an optical density at 600 nm (OD600) of 0.6, it was induced with 0.15%
(wt/vol) arabinose and supplemented with 0.15% (wt/vol) glucose. The bacteria were harvested as
described for PyoS5 and resuspended in 10 mM Tris-HCl (pH 8.0) and 0.25% (wt/vol) lithium diiodosali-
cylic acid (LIS), sonicated as described for PyoS5, and centrifuged at 4,000  g for 20 min at 4°C. The
supernatant was collected, and the pellet was resuspended in fresh buffer and centrifuged again. Both
supernatants were ultracentrifuged at 200,000  g for 45 min at 4°C. The pellet was homogenized in
10 mM Tris-HCl (pH 8.0), 0.25% (wt/vol) LIS, and 2% (vol/vol) Triton X-100 and ultracentrifuged again. The
resulting pellet was homogenized in 10 mM Tris-HCl (pH 8.0) and ultracentrifuged again. The resulting
pellet was homogenized in 10 mM Tris-HCl (pH 8.0) plus 2% (wt/vol) -OG and 5 mM ethylenediaminetet-
raacetic acid (EDTA) and ultracentrifuged again. FptA was purified from the supernatant by anion-
exchange chromatography. A 5-ml HiTrap DEAE fast flow (FF) column was equilibrated in buffer E (50 mM
Tris-HCl [pH 7.5], 1% [wt/vol] -OG, 5 mM EDTA) and gradient eluted with buffer F (buffer E plus 1 M LiCl).
This was followed by 16/60 Sephacryl 300 size exclusion chromatography in buffer E and anion-exchange
chromatography on a Mono Q 4.6/100 PE column in buffer E, with gradient elution with buffer F.
Protein quantification. All protein concentrations were measured using the absorbance at 280 nm,
which was converted to concentration using the sequence-based predicted molar extinction coefficient
(ExPASy ProtParam). The presence of scattering impurities, such as protein aggregates, was checked for
by measuring the absorbance at 320 nm. All protein masses were confirmed by denaturing electrospray
ionization (ESI) mass spectrometry (MS) performed on proteins diluted in formic acid.
Pyocin cytotoxicity assays. P. aeruginosa YHP17 cells were grown to an OD600 of 0.6, and 200 l of
the culture was mixed with melted, 50°C, soft LB agar (0.75% [wt/vol] agar) and poured over an LB agar
plate. Once the plate had set, 2.5 l of each bacteriocin concentration was spotted onto the plate. The
plates were left to dry and then incubated at 37°C overnight.
LPS-derived polysaccharide isolation. LPS-derived polysaccharides were isolated as described
previously (13). Briefly, 1 liter of cells was grown for 20 h at 37°C, pelleted at 6,000  g for 20 min, and
resuspended in 10 ml of 50 mM Tris (pH 7.5), 2 mg/ml lysozyme, and 0.5 mg/ml DNase I. Cells were lysed
by sonication, as described for PyoS5 isolation, the lysate was incubated for 30 min at RT, and then
0.2 mM EDTA added. An equal volume of aqueous phenol was then added and the mixture heated for
20 min at 70°C with mixing. The solution was incubated on ice for 30 min and centrifuged at 7,000  g
for 20 min, and the aqueous upper layer was extracted. Proteinase K (0.05 mg/ml) was added and the
solution dialyzed overnight against 5 liters of distilled water (dH2O), followed by dialysis against 5 liters
of fresh dH2O for 5 h. LPS was pelleted by ultracentrifugation for 1 h at 100,000  g and the pellet
resuspended in 10 ml dH2O. The suspension was heated at 60°C for 30 min, acetic acid was added, and
the mixture was heated at 96°C for 1.5 h. Lipid A was pelleted by centrifugation at 13,500  g for 3 min,
and the supernatant, which contains the polysaccharide, was extracted with 10 ml chloroform. The
aqueous phase was then lyophilized.
Biophysical methods. Native mass spectrometry was performed in 100 mM ammonium acetate
buffer, with the exception of TonB1, which was analyzed in 200 mM ammonium acetate buffer.
SPR was performed on a Biacore T200 instrument. A series S sensor chip CM5 (GE Life Sciences) was
docked and primed into HBS-OG buffer (25 mM HEPES [pH 7.5], 150 mM NaCl, 1% [wt/vol] -OG). This
buffer was used as a running buffer for all SPR experiments.
For amine coupling using the Amine Coupling kit (GE Healthcare), ligand proteins were desalted into
immobilization buffer (25 mM potassium phosphate [pH 7.5], 50 mM NaCl) and diluted 10-fold in 10 mM
sodium acetate (pH 5.0; GE Life Sciences).
For thiol coupling using the Thiol Coupling kit (GE Healthcare), ligand proteins were incubated with
10 mM dithiothreitol (DTT) for 2 h and then desalted into immobilization buffer diluted 10-fold in 10 mM
sodium acetate (pH 5.0; GE Life Sciences) immediately before immobilization.
Analyte proteins were desalted into HBS-OG buffer before application. The contact time for SPR was
set to 120 s, the dissociation time to 600 s, and the flow rate to 30 l/min. Lower analyte concentrations
were applied first.
ITC was performed using a MicroCal iTC200 instrument at 25°C in 0.2 M sodium phosphate buffer (pH
7.5). Proteins in the syringe were at a concentration of 150 M, and polysaccharides in the cell were at
a concentration of 7 mg/ml, which was estimated to be 30 M based on a molecular weight of 10 kDa
and the assumption that CPA constitutes 5% of the LPS polysaccharides. The data were fitted to a
one-binding-site model in the MicroCal LLC Origin software. As the CPA concentration is estimated, the
observed stoichiometry is unlikely to be correct, while ΔH, ΔS, and Kd are unaffected by the analyte
concentration. Errors reported in the text are standard deviations of the average results from two
experiments.
SAXS data were collected at the B21 beamline at Diamond Light Source proteins following in-line size
exclusion chromatography on a Superdex 200 column and processed using ScÅtter and ATSAS (32, 33).
Guinier approximation analysis and P(r) distributions were determined using ScÅtter. Dummy atoms
were fit using multiple parallel runs of DAMMIF (34) and refined using DAMMIN (reference). Bead models
were converted to maps using Situs (35) and structures fit into the envelopes using Chimera (36). CRYSOL
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from the ATSAS suite was used to generate the theoretical curve of the crystal structure and to fit it to
the SAXS data.
(i) Circular dichroism. Proteins were analyzed at 0.1 mg/ml in 10 mM potassium phosphate buffer
(pH 7.5) and 20 mM NaCl using a Jasco J-815 spectropolarimeter. Spectra were measured between
260 nm and 190 nm at a digital integration time of 1 s and a 1-nm bandwidth. Each sample spectrum was
measured in quadruplicate and averaged. Molar ellipticity was calculated by subtracting the baseline
from sample spectra and dividing by the molecular weight, molar concentration, and pathlength in
millimeters. Thermal melting curves for proteins were measured at 222 nm between 20°C and 86°C and
4-parameter sigmoidal melting curves were fit to the equation f  y0  a/(1e(x 	 x0)/b) using non-linear
regressions in SigmaPlot to determine the melting temperature (Tm), where x is the temperature, x0 is the
Tm, f is molar ellipticity, y0 is the minimal molar ellipticity, and b is a fitting parameter.
(ii) Size exclusion multiangle light scattering. Proteins were separated in 50 mM Tris (pH 7.5) and
150 mM NaCl using a Superdex 200 10/300 GL column and detected by a Wyatt Dawn HELEOS-II 8-angle
light-scattering detector and a Wyatt Optilab rEX refractive index monitor linked to a Shimadzu
high-performance liquid chromatography (HPLC) system.
X-ray crystallography. Pyocin S5 was concentrated to 16 mg/ml in 25 ml Tris-HCl (pH 7.5) and
150 mM NaCl using a VivaSpin 20 column with a 30-kDa molecular weight cutoff (Sartorius). The
crystallization screens Index (Hampton Research) and PACT, JCSG, and Morpheus (Molecular Dimen-
sions) were used to screen for crystals. Crystals were grown in a vapor diffusion sitting drop setup under
JCSG screen (Molecular Dimensions) condition C7 (10% [wt/vol] polyethylene glycol 3000 [PEG 3000],
0.1 M sodium acetate, 0.1 M zinc acetate [pH 4.5]) at 18°C. The drops contained 100 nl protein and 100
nl buffer. The cryoprotectant solution was 25% glycerol, 10% (wt/vol) PEG 3000, 0.1 M sodium acetate,
and 0.1 M zinc acetate (pH 4.5) for cooling the crystals in liquid nitrogen. Diffraction data were collected
at beamline ID30A-3 at the European Synchrotron Radiation Facility (ESRF) at a wavelength of 0.9679 Å
using an Eiger detector. We collected 225° of data with 0.15° oscillation. The transmission was 20%, and
the exposure time was 0.010 s.
The raw data were analyzed in Dials, revealing a P21 space group and yielding a 98.8% complete set
of indexed diffraction spots but no anomalous signal. Molecular replacement was carried out using ColIa
residues 450 to 624 in Phaser and yielded electron density for the pore-forming domain of PyoS5. The
lack of density for the remainder of the protein indicated that the phases, obtained from ColIa, were not
sufficient to build a model for the whole protein.
Improved phases were obtained from anisotropy correction of the same data set using Staraniso in
AutoProc (37, 38), which allowed a weak anomalous signal to be detected. The partial model from
molecular replacement from Dials and the anomalous data from AutoProc were combined for MR-SAD
phasing using Phaser (39). An anomalous substructure containing eight metal ions was identified. Based
on the type of metal present under the crystallization conditions, these were assumed to be Zn2. The
result was additional, visible helical density beyond the pore-forming domain.
Iterations of model building into the visible helical density in Coot and refinement against the
complete Dials data set in Buster version 2.10.3 resulted in a model of PyoS5. The model was optimized
in Coot (40), followed by one crystallographic refinement in Buster, and then followed by model
optimization in Coot and one refinement in Phenix 1.12 (41). Up to then, the whole model was treated
as one TLS group. At this point, four new translation-libration-screw-rotation (TLS) groups were created
based on similar B-factors as determined in Phenix, comprising residues 40 to 212, 213 to 338, 339 to 395,
and 395 to 505. This increased the Rwork and Rfree upon refinement, indicating that the use of multiple
TLS groups made the model worse. The refinement process was therefore continued with the whole
model treated as one TLS group.
At the end of the model optimization and refinement, the Rwork was 0.212 and the Rfree was 0.272.
MolProbity (42) was used to validate the structure and assess its quality, resulting in a MolProbity score
of 1.57. At the end of this validation process, the Rwork was 0.225 and the Rfree was 0.275. Figures of the
crystal structure were created using CCP4MG (43) and PyMOL (44).
Fluorescence microscopy. (i) Fluorescent labeling of proteins. Bacteriocins were fluorescently
labeled using maleimide AF488 labels via an engineered C-terminal cysteine. To reduce the cysteine, the
protein was mixed in a 1:9 ratio with DTT to yield a concentration of 10 mM DTT and incubated for 2 h
at RT. To remove aggregates, the protein was centrifuged at 16,000  g for 1.5 min and the supernatant
transferred to a new tube. The supernatant was then applied to a 5-ml HiTrap desalting column and
desalted into 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 1% (wt/vol) -OG. The protein concentration
was measured, and maleimide AF488 was immediately added in 3-fold excess. The reaction was allowed
to proceed for 1 h while mixing by rotary inversion in the dark at RT. Then, the reaction was quenched
by adding DTT to a final concentration of 5 mM. The solution was centrifuged and desalted as described
before. The absorbance at 280 nm and 494 nm was measured using a V-550 UV-visible spectrophotom-
eter (Jasco). Labeling efficiency was determined as described in the manufacturer’s protocol (Alexa Fluor
488 protein-labeling kit; Thermo Scientific). All fluorescently labeled proteins used for microscopy were
labeled with more than 95% efficiency.
(ii) Fluorescent labeling of bacteria. Coverslips were cleaned by water bath sonication at 50°C for
15 min in 2% Neutracon (Decon) solution, washed in double-distilled water (ddH2O), and air dried.
Bacteria were grown overnight in LB medium. One milliliter of this overnight culture was
pelleted, resuspended in 10 ml of supplemented M9 medium, and grown until an OD600 of 0.6 was
reached. Six hundred microliters of this culture was used per condition. All pelleting steps were
performed at 7,000  g for 3 min at RT.
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For CCCP treatment, CCCP was added to a final concentration of 100 M from a 10 mM stock in
dimethyl sulfoxide (DMSO) to the bacteria before the addition of the fluorescently labeled protein. The
bacteria were incubated with CCCP while mixing by rotary inversion at RT for 5 min, while all other
samples were incubated without CCCP for the same time. Fluorescently labeled protein was then added
to a concentration of 1 M and the sample incubated in the dark while mixing by rotary inversion for
20 min at RT.
For trypsin treatment, trypsin was added to a final concentration of 0.1 mg/ml immediately after the
incubation with the fluorophore-labeled pyocin. The bacteria were incubated with or without trypsin at
30°C for 1 h at 120 rpm.
Subsequently, bacteria were washed three times in supplemented M9, where each wash consisted of
pelleting the bacteria, removing the supernatant, resuspending the pellet in 50 l by repeated pipetting
(10 times) with a P20 pipette, transferring the 50 l to a new tube with 450 l of supplemented M9, and
vortexing. The bacteria were resuspended in a final volume of 30 l. Three microliters was applied to an
agar pad for microscopic analysis. Agar pads were prepared using Gene Frames (Thermo Scientific) as
follows. Supplemented M9 agar (1% [wt/vol]) was prepared and 190 l pipetted into the Gene Frame.
Using a coverslip, the surface was flattened and excess agar removed. Once the agar solidified, the
coverslip was removed, the bacterial suspension was added, and a new coverslip was attached to the
adhesive side of the Gene Frame.
Image collection. All images were collected on an Oxford Nanoimager S microscope at 100-ms
exposure. For every image, 200 frames were collected and averaged. Green fluorescence (excitation,
473 nm; emission, 425/50 nm) was measured at 35% laser power.
Data analysis. In ImageJ, the 200 collected frames per image were merged using the command “Z
project.” Bacterial cells and background were identified in transillumination images using Trainable Weka
Classifier. Regions of interest were transferred to green fluorescence images and the mean fluorescence
of cells, signal, and background noise quantified. Each image contained a minimum of 15 bacterial cells.
For each repeat, a minimum of six images were collected per sample, and three independent experi-
ments were performed for each experiment. As a result, a minimum of 270 bacterial cells were quantified
for each sample. Student’s t tests were performed to determine P values.
Sequence and structure comparisons. Sequences were compared using NCBI BLASTn and BLASTp
(45), MUSCLE (46), and jackhmmer (47). Similar structures were searched for using NCBI VAST (48) and
eFOLD (49).
Data availability. The data supporting the findings of the study are available from the correspond-
ing author upon request. The crystallography data from this publication have been deposited to the PDB
database (https://www.rcsb.org/) and assigned the identifier 6THK.
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